Hematology · Beta-Thalassemia

Advanced Therapies: Maturation Agents and Gene Therapy

At a Glance

Advanced beta-thalassemia treatments may reduce transfusions or achieve transfusion independence, but gene therapy and donor stem cell transplant require intensive chemotherapy, hospitalization, and carry serious risks. Eligibility depends on age, genotype, health, and access.

For many years, the only path to a potential cure for beta-thalassemia was an allogeneic bone marrow transplant. Today, the landscape is expanding. Newer medications can help your body produce better red blood cells, while gene therapies offer the possibility of modifying your own stem cells to produce functional hemoglobin ^[1]^[2]. It is vital to understand that while these therapies are incredibly promising, they are not universally available, they require rigorous eligibility screening, and they carry significant short- and long-term risks.

Medical Therapies to Reduce Transfusions

These therapies do not change your genetics, but they intervene in the way your body develops red blood cells.

Luspatercept (Reblozyl): This is a red blood cell maturation agent given as a subcutaneous (under the skin) injection every three weeks ^[3]. In a major study of adults with transfusion-dependent thalassemia (the BELIEVE trial), about 21% of patients achieved the primary goal of reducing their transfusion burden by at least one-third during a strict 12-week period ^[4]. When looking at the data more broadly, approximately 70% of patients achieved this reduction at some point during the trial. It is not a guaranteed cure, and individual responses vary. Common side effects include bone pain, fatigue, and dizziness ^[5].
Mitapivat (Aqvesme): This is a pyruvate-kinase activator, an oral medication (a pill) that boosts an enzyme providing energy to red blood cells, helping them live longer ^[6]. Dosing is titrated carefully by your doctor according to the product label. It has shown promise in improving hemoglobin levels in eligible patients, but requires its own specific monitoring profile.

Gene Therapy: A Potentially Curative Approach

Gene therapy is a specialized process where your own hematopoietic stem cells (the “mother cells” that create all blood) are collected, genetically modified in a lab, and then returned to you ^[7]. Because these use your own cells, there is no risk of donor-related graft-versus-host disease (GVHD) ^[8]. However, this does not mean the procedure is risk-free.

Two major gene therapies are approved in certain jurisdictions (such as the US/FDA for specific ages and genotypes):

Betibeglogene autotemcel (Zynteglo): Uses a modified virus to “add” a functional beta-globin gene into your stem cells ^[9]. In select clinical trials, many eligible patients achieved transfusion independence ^[10].
Exagamglogene autotemcel (Casgevy): Uses CRISPR-Cas9 gene-editing technology to edit an erythroid regulatory region in your DNA. This edit essentially restarts the production of fetal hemoglobin (HbF) to compensate for the missing adult hemoglobin ^[11].

The Conditioning Process and Severe Risks

Gene therapy is not a simple injection or a “one-and-done” cure. To make room for the new, modified stem cells to engraft, you must undergo myeloablative conditioning using a powerful chemotherapy drug called busulfan ^[12].

This phase carries immense, life-altering risks:

Infertility: Busulfan often causes permanent ovarian failure and infertility. You must discuss fertility preservation (freezing eggs or sperm) beforehand, but you must also know that preservation is never 100% guaranteed ^[13]^[14].
Severe Toxicities: Risks include prolonged cytopenias (dangerously low blood counts), severe mucositis (painful mouth and gut sores), pulmonary and renal toxicity, and secondary malignancies (cancers later in life).
Liver Disease: A life-threatening condition called veno-occlusive disease (VOD) can occur, blocking the small blood vessels in the liver ^[12].
Prolonged Hospitalization: You will spend weeks to months in the hospital with a suppressed immune system, at high risk for severe infections ^[15].

Furthermore, achieving transfusion independence does not instantly erase decades of prior iron overload. Iron chelation and MRI surveillance will likely continue long after the procedure.

Allogeneic Stem Cell Transplant (HSCT)

An allogeneic bone marrow transplant (using donor cells) remains a potentially curative option. Outcomes are heavily dependent on the patient’s age, extent of existing organ damage (iron overload), and center experience. When performed in younger patients with a perfectly matched sibling donor, survival outcomes are generally very favorable ^[16]^[17].

However, allogeneic HSCT carries unique and severe risks, particularly Graft-Versus-Host Disease (GVHD), where the donor’s immune cells attack the patient’s body ^[18]. Other risks include graft failure and treatment-related mortality ^[15]. Choosing between an allogeneic transplant and autologous gene therapy requires extensive discussions with a specialized transplant center to weigh donor availability against conditioning and long-term risks ^[19].

Common questions in this guide

Which medicines can reduce transfusions in beta-thalassemia?

Luspatercept is an injection given under the skin about every three weeks and may reduce the number of transfusions needed. Mitapivat is an oral medicine that helps red blood cells use energy and may improve hemoglobin in eligible people. Neither medicine is a guaranteed cure, and response and monitoring needs vary.

How does gene therapy work for beta-thalassemia?

Your own blood-forming stem cells are collected, modified or edited in a laboratory, and returned after chemotherapy creates space for them to grow. Zynteglo adds a working beta-globin gene, while Casgevy edits DNA to increase fetal hemoglobin. These treatments may lead to transfusion independence in eligible patients, but they require intensive treatment and are not risk-free.

What are the main risks of beta-thalassemia gene therapy?

The chemotherapy preparation, usually involving busulfan, can cause infertility, dangerously low blood counts, painful mouth or gut sores, organ injury, blockage of small blood vessels in the liver, severe infections, and later cancers. Treatment often requires weeks to months in the hospital with a weakened immune system. Fertility preservation should be discussed beforehand, but it cannot guarantee future fertility.

Are Zynteglo and Casgevy available to everyone with beta-thalassemia?

No. Eligibility depends on factors such as age, the exact genetic subtype, transfusion history, overall health, and the rules in the country where treatment is offered. A specialized treatment center must complete medical screening and explain whether the potential benefits outweigh the risks.

Does becoming transfusion-independent remove iron overload?

No. Iron accumulated from earlier transfusions can remain in the body even if regular transfusions stop. Iron-chelating medicine and MRI checks of organs such as the liver and heart may continue until specialists confirm that iron levels are safe.

How is donor stem cell transplant different from gene therapy?

An allogeneic transplant uses blood-forming stem cells from a donor and can cause graft-versus-host disease, graft failure, or treatment-related death. Autologous gene therapy uses your own cells, so it does not carry the donor-related graft-versus-host disease risk, but it still requires intensive chemotherapy conditioning and has serious risks. A transplant center should compare donor matching, age, existing iron-related organ damage, and long-term risks with you.

Curated prompts to bring to your next appointment.

1.Based on my age, exact genotype, and country guidelines, am I legally and medically a candidate for luspatercept or mitapivat?
2.If I pursue gene therapy, what specific fertility preservation options (like egg or sperm freezing) are available at this center, and what are the limitations?
3.How many patients at this facility have undergone autologous gene therapy or HSCT, and what has their long-term success with transfusion independence been?
4.If a matched sibling donor is available, how would you compare the risks of graft-versus-host disease (GVHD) in a transplant versus the conditioning risks of gene therapy?
5.What is the plan for monitoring my liver and heart health if my transfusion burden drops but my iron levels remain high during treatment?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

Luspatercept and mitapivat may reduce transfusion needs or improve hemoglobin, but neither is a guaranteed cure and individual responses vary.
Zynteglo adds a working beta-globin gene, while Casgevy uses CRISPR gene editing to increase fetal hemoglobin in eligible patients.
Autologous gene therapy avoids donor-related graft-versus-host disease but requires busulfan-based conditioning, prolonged hospitalization, and carries risks such as infertility, infections, and liver injury.
Allogeneic stem cell transplant may be curative, especially for selected younger patients with a matched sibling donor, but it carries risks including graft-versus-host disease and graft failure.
Transfusion independence does not immediately eliminate prior iron overload, so iron chelation and MRI surveillance may continue after treatment.

References (19)

1
Drug safety in thalassemia: lessons from the present and directions for the future.
Grech L, Sultana J, Borg K, Borg J
Expert opinion on drug safety 2021; (20(8)):937-947 doi:10.1080/14740338.2021.1919081.
PMID: 33877003
2
Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.
Inam Z, Han H, Webb J, Delaney M
Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.
PMID: 41223813
3
The use of luspatercept for thalassemia in adults.
Cappellini MD, Taher AT
Blood advances 2021; (5(1)):326-333 doi:10.1182/bloodadvances.2020002725.
PMID: 33570654
4
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.
Cappellini MD, Viprakasit V, Georgiev P, et al.
The Lancet. Haematology 2025; (12(3)):e180-e189 doi:10.1016/S2352-3026(24)00376-4.
PMID: 39947215
5
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study.
Taher AT, Viprakasit V, Kattamis A, et al.
Blood advances 2025; (9(23)):6108-6119 doi:10.1182/bloodadvances.2025016554.
PMID: 40875596
6
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Taher AT, Al-Samkari H, Aydinok Y, et al.
Lancet (London, England) 2025; (406(10498)):33-42 doi:10.1016/S0140-6736(25)00635-X.
PMID: 40544857
7
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA, Walters MC, Kwiatkowski J, et al.
The New England journal of medicine 2018; (378(16)):1479-1493 doi:10.1056/NEJMoa1705342.
PMID: 29669226
8
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.
Leonard A, Bertaina A, Bonfim C, et al.
Cytotherapy 2022; (24(3)):249-261 doi:10.1016/j.jcyt.2021.09.003.
PMID: 34879990
9
Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.
Locatelli F, Thompson AA, Kwiatkowski JL, et al.
The New England journal of medicine 2022; (386(5)):415-427 doi:10.1056/NEJMoa2113206.
PMID: 34891223
10
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
Kwiatkowski JL, Walters MC, Hongeng S, et al.
Lancet (London, England) 2024; (404(10468)):2175-2186 doi:10.1016/S0140-6736(24)01884-1.
PMID: 39527960
11
An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.
Handgretinger R, Mezger M
Expert opinion on biological therapy 2024; (24(9)):883-888 doi:10.1080/14712598.2024.2399134.
PMID: 39222044
12
Alternative conditioning regimens for hemoglobinopathy gene therapy: balancing efficacy, toxicity, and the next frontier.
Sharma A, Corbacioglu S
Blood advances 2026; (10(18)):6118-6123 doi:10.1182/bloodadvances.2026019856.
PMID: 42418372
13
Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience.
Rahal I, Galambrun C, Bertrand Y, et al.
Haematologica 2018; (103(7)):1143-1149 doi:10.3324/haematol.2017.183467.
PMID: 29599204
14
Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel.
Mirza A, Ritsert ML, Tao G, et al.
Blood advances 2025; (9(1)):29-38 doi:10.1182/bloodadvances.2024014104.
PMID: 39418614
15
Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Transfusion-Dependent Thalassemia: A Systematic Review and Meta-Analysis.
Xiao H, Huang Q, Lai Y, Liu R
Transplantation and cellular therapy 2025; (31(2)):101.e1-101.e12 doi:10.1016/j.jtct.2024.12.001.
PMID: 39647520
16
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
Shenoy S, Angelucci E, Arnold SD, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017; (23(4)):552-561 doi:10.1016/j.bbmt.2017.01.009.
PMID: 28065838
17
Hematopoietic Stem Cell Transplantation in Thalassemia.
Strocchio L, Locatelli F
Hematology/oncology clinics of North America 2018; (32(2)):317-328 doi:10.1016/j.hoc.2017.11.011.
PMID: 29458734
18
Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience.
Yesilipek MA, Uygun V, Kupesiz A, et al.
Bone marrow transplantation 2022; (57(5)):760-767 doi:10.1038/s41409-022-01613-w.
PMID: 35210564
19
Current therapeutic landscape of β-thalassemia: focus on gene therapy.
Cheng AN, Kwiatkowski JL
Therapeutic advances in rare disease 2026; (7()):26330040261433028 doi:10.1177/26330040261433028.
PMID: 41919270

This page explains advanced beta-thalassemia treatments for informational purposes only and does not constitute medical advice. A specialist hematology or transplant team should assess your eligibility, fertility-preservation options, risks, and monitoring needs.

Get notified when new evidence is published on beta-thalassemia HBB/LCRB.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents